Education
About Us
Working with TipRanks
Follow Us
Catheter Precision (VTAK)
:VTAK
Top Page
Catheter Precision
(NYSE MKT:VTAK)
41Neutral
Catheter Precision (VTAK) vs. S&P 500 (SPY)
Market Cap
$2.99M
Dividend YieldN/A
Average Volume (3M)159.17K
Price to Earnings (P/E)―
Beta (1Y)2.08
Revenue Growth27.07%
EPS Growth95.82%
CountryUS
Employees14
SectorHealthcare
Sector Strength64
IndustryMedical Equipment & Supplies
Share Statistics
EPS (TTM)-12.13
Shares Outstanding8,004,633
10 Day Avg. Volume93,208
30 Day Avg. Volume159,174
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)8.43
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Catheter Precision Business Overview & Revenue Model
Company DescriptionCatheter Precision (VTAK) is a medical technology company specializing in the development and commercialization of innovative products for cardiac electrophysiology. The company focuses on providing advanced solutions for the diagnosis and treatment of cardiac arrhythmias, leveraging its expertise in catheter-based technologies and mapping systems.
How the Company Makes MoneyCatheter Precision makes money primarily through the sale of its specialized medical devices and related technologies to hospitals, clinics, and healthcare providers. The company generates revenue by selling its proprietary catheters and cardiac mapping systems, which are used in the diagnosis and treatment of heart rhythm disorders. Additionally, Catheter Precision may earn revenue through partnerships, licensing agreements, and collaborations with other medical technology companies and healthcare institutions. These partnerships can help expand the reach of its products and enhance its market presence. Factors contributing to its earnings include advancements in product technology, regulatory approvals, and its ability to effectively market and distribute its products within the competitive healthcare industry.
Catheter Precision Financial Statement Overview
Summary
Catheter Precision faces substantial financial difficulties characterized by declining revenues, substantial losses, and negative cash flows. While there is some stability in equity financing, the company needs to address its profitability and liquidity challenges to improve financial health.Income Statement
The company shows significant challenges in profitability with negative net income and EBIT margins. Revenue has declined in recent years, although there's a minor increase in the TTM period. The company struggles with high operating losses, impacting its overall income performance.35
Negative
Balance Sheet
The balance sheet reveals moderate leverage with a debt-to-equity ratio and declining stockholders' equity over time. The equity ratio remains relatively stable, suggesting some level of asset financing through equity, but overall financial stability is a concern due to recurring losses.45
Neutral
Cash Flow
Cash flow statements show consistent negative operating cash flows, with free cash flow also being negative. The company relies on financing activities to sustain operations, indicating potential liquidity issues. The negative cash flow to net income ratios further highlight the cash flow challenges.40
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 399.00K | 442.00K | 14.00K | 22.00K | 4.41M | 7.20M | Gross Profit |
| 361.00K | 412.00K | -147.00K | -1.54M | -1.08M | -1.65M | EBIT |
| -10.79M | -78.12M | -26.96M | -29.27M | -36.06M | -57.73M | EBITDA |
| -10.46M | -15.11M | -22.37M | -27.70M | -33.30M | -54.94M | Net Income Common Stockholders |
| -11.68M | -70.57M | -26.86M | -25.07M | -36.05M | -56.96M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 3.56M | 3.56M | 15.86M | 15.04M | 23.91M | 30.58M | Total Assets |
| 30.74M | 30.74M | 16.84M | 21.04M | 33.44M | 44.08M | Total Debt |
| 372.00K | 372.00K | 124.17K | 2.26M | 4.88M | 3.50M | Net Debt |
| -3.19M | -3.19M | -15.73M | -12.78M | -19.02M | -11.09M | Total Liabilities |
| 9.54M | 9.54M | 7.58M | 7.37M | 12.29M | 10.93M | Stockholders Equity |
| 21.19M | 21.19M | 9.26M | 13.67M | 21.15M | 33.15M |
| Cash Flow | Free Cash Flow | ||||
| -8.38M | -20.70M | -22.59M | -27.89M | -28.37M | -33.44M | Operating Cash Flow |
| -8.30M | -20.62M | -22.57M | -27.63M | -28.30M | -33.17M | Investing Cash Flow |
| -85.00K | -61.00K | 21.00K | 3.80M | 15.93M | -16.03M | Financing Cash Flow |
| 4.07M | 8.39M | 23.36M | 14.96M | 21.69M | -526.00K |
Catheter Precision Technical Analysis
Negative
0.38
Price Trends
0.38
Negative
0.41
Negative
1.22
Negative
Market Momentum
<0.01
Negative
48.65
Neutral
48.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTAK, the sentiment is Negative. The current price of 0.38 is above the 20-day moving average (MA) of 0.36, below the 50-day MA of 0.38, and below the 200-day MA of 1.22, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 48.65 is Neutral, neither overbought nor oversold. The STOCH value of 48.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VTAK.
Catheter Precision Risk Analysis
Catheter Precision disclosed 78 risk factors in its most recent earnings report. Catheter Precision reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Catheter Precision Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $1.16B | 26.85 | 25.01% | ― | 8.52% | -32.91% | |
59 Neutral | $161.64M | ― | -144.19% | ― | 0.55% | -8.47% | |
55 Neutral | $9.10M | ― | -42.78% | ― | -41.41% | 23.95% | |
50 Neutral | $60.25M | ― | -18.09% | ― | -14.70% | 67.34% | |
50 Neutral | $127.30M | ― | -32.64% | ― | 17.98% | 56.04% | |
49 Neutral | $6.86B | 0.72 | -52.93% | 2.49% | 20.83% | 1.11% | |
41 Neutral | $2.99M | ― | -67.36% | ― | 27.07% | 95.82% |
* Healthcare Sector Average
Performance Comparison
VTAK
Catheter Precision
0.38
-4.48
-92.18%
ICAD
iCAD
2.14
0.53
32.92%
NURO
Neurometrix
4.52
0.27
6.35%
STXS
Stereotaxis
1.88
-0.73
-27.97%
MDXG
MiMedx Group
7.74
0.04
0.52%
KRMD
REPRO-MED Systems
2.61
0.25
10.59%
Catheter Precision Corporate Events
Executive/Board Changes
Catheter Precision Announces New CFO Appointment
Neutral
Jan 7, 2025
Catheter Precision, Inc. has appointed Philip Anderson as the new Chief Financial Officer, effective January 6, 2025. The appointment signifies a leadership change aimed at enhancing the company’s financial strategy. With Anderson’s extensive experience across various industries, including technology and beverage distillation, the company anticipates strengthening its financial management and reporting. Anderson’s compensation package includes a base salary, stock options, and bonus eligibility, indicating a robust incentive structure to align his interests with the company’s growth objectives.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.